An audible sigh of relief was heard this morning that, at last, the U.S. 2016 election is over. In the end, in what was an oft-controversial, hot-tempered and…

Canadian cancer biotech Oncolytics announced alongside its financials that its long-standing president and CEO, Brad Thompson, will be leaving the company “…

It’s that time of year when biopharmas sneak out negative R&D news amid a swath of financial data, and the FierceBiotech team has delved deep into the…

The candidate just won a breakthrough designation from the FDA and priority medicine status from the EMA in July, with an FDA submission expected next year.

Mologen is seeking to raise €16 million to fund a suite of trials of its TLR9 agonist in patients with colorectal cancer, small cell lung cancer and HIV.

Abivax's share price has surged more than 160% in a little more than one trading session on the back of news regarding its HIV collaboration.

Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

Financials